← Back to all trials
Recruiting
NCT06736587
Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers
Conditions: Autoimmune Diseases
Sex: All
Ages: 19 Years – 55 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 84
Sponsor: Daewoong Pharmaceutical Co. LTD.
Location: Seoul National University Hospital Seoul
Summary
The safety and tolerability of single and multiple administration of DWP212525
Eligibility Criteria
Inclusion Criteria:
1. Healthy adult volunteers aged 19 to 55 years
2. Those with a body weight ≥ 50.0 kg to ≤ 90.0 kg with a body mass index (BMI) of ≥ 18.0 kg/m2 to ≤ 30.0 kg/m2
3. Received a sufficient explanation on this study
4. Eligible as subjects in the study
Exclusion Criteria:
1. History of diseases such as clinically significant disease of hepatobiliary
2. Following conditions applicable to clinically significant acute or chronic infections or the past history confirmed via an interview
3. Hemato-oncologic diseases, including malignant tumor diagnosis
4. Past history of tuberculosis infection or confirmed tuberculosis in the IGRA test and chest X-ray test
Source: ClinicalTrials.gov (NCT06736587). StuddyBuddy aggregates publicly available trial information.
